ASP2074

N/A

Report date: 2026/03/19 17:16:30

Base Information

Drug NameASP2074

Drug Alias NameASP-2074ASP2074

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionTetraspanin-8 inhibitorsCD3 T-cell engagers

TargetsTetraspanin-8T cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesJapan

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAstellas Pharma Global Development Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAstellas Pharma Global Development Inc

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A